Research programme: Bcr-Abl kinase inhibitors - Pfizer Global Research and Development

Drug Profile

Research programme: Bcr-Abl kinase inhibitors - Pfizer Global Research and Development

Alternative Names: PD 166326; PD 180970

Latest Information Update: 03 Aug 2009

Price : $50

At a glance

  • Originator Pfizer
  • Class Antineoplastics; Pyridones; Pyrimidines; Small molecules
  • Mechanism of Action Bcr-abl tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Chronic myeloid leukaemia

Most Recent Events

  • 03 Aug 2009 Discontinued - Preclinical for Chronic myeloid leukaemia in USA (unspecified route)
  • 15 May 2005 A preclinical study has been added to the cancer pharmacodynamics section
  • 18 Dec 2003 Data presented at the 45th Annual Meeting of the American Society of Hematology (ASH-2003) have been added to the Cancer pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top